<DOC>
	<DOCNO>NCT02868255</DOCNO>
	<brief_summary>project study develop anti-Signal Regulatory Protein α ( SIRPα ) antibody ( Ab ) new immunotherapy strategy cancer . Samples harvest hepatocellular carcinoma ( HCC ) ovarian cancer patient use evaluation SIRP-CD47 expression effect anti-human Signal Regulatory Protein ( hSIRP ) Ab various cellular type patient healthy volunteer .</brief_summary>
	<brief_title>Myeloid Derived Suppressor Cells Control Signal Regulatory Protein-alpha : Investigation Hepatocellular Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<criteria>adult HCC patient ( BCLC stage accept ) patient consent use biological sample patient cancer hepatitis C B positive HCC treatment chemoembolization 3 month Sorafenib treatment within month prior collection underage guardianship patient</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Biobank analysis</keyword>
	<keyword>Effect evaluation drug</keyword>
	<keyword>patient-derived cell</keyword>
	<keyword>SIRPα/CD47 expression</keyword>
</DOC>